| Literature DB >> 35562876 |
Alejandro Hurtado1, Alaa A A Aljabali2, Vijay Mishra3, Murtaza M Tambuwala4, Ángel Serrano-Aroca1.
Abstract
Alginate is an excellent biodegradable and renewable material that is already used for a broad range of industrial applications, including advanced fields, such as biomedicine and bioengineering, due to its excellent biodegradable and biocompatible properties. This biopolymer can be produced from brown algae or a microorganism culture. This review presents the principles, chemical structures, gelation properties, chemical interactions, production, sterilization, purification, types, and alginate-based hydrogels developed so far. We present all of the advanced strategies used to remarkably enhance this biopolymer's physicochemical and biological characteristics in various forms, such as injectable gels, fibers, films, hydrogels, and scaffolds. Thus, we present here all of the material engineering enhancement approaches achieved so far in this biopolymer in terms of mechanical reinforcement, thermal and electrical performance, wettability, water sorption and diffusion, antimicrobial activity, in vivo and in vitro biological behavior, including toxicity, cell adhesion, proliferation, and differentiation, immunological response, biodegradation, porosity, and its use as scaffolds for tissue engineering applications. These improvements to overcome the drawbacks of the alginate biopolymer could exponentially increase the significant number of alginate applications that go from the paper industry to the bioprinting of organs.Entities:
Keywords: alginate; biopolymer; composites; enhanced properties; hydrogel
Mesh:
Substances:
Year: 2022 PMID: 35562876 PMCID: PMC9102972 DOI: 10.3390/ijms23094486
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Application areas of alginate and its specific uses.
| Area | Specific Use | Reference |
|---|---|---|
| Biotechnology, bioengineering, biomedicine, and clinical | Dressings for wounds and burns | [ |
| Heavy metal chelator | [ | |
| Scaffolding in tissue engineering | [ | |
| Controlled release | [ | |
| 3D bio-printing | [ | |
| Prosthesis, dental molds and impression materials | [ | |
| Immobilization of enzymes and cells | [ | |
| Pharmaceutical industry | Food supplements | [ |
| Treatment for gastric reflux | [ | |
| Cancer therapy | [ | |
| Chemical, textile, packaging and construction industry | Cosmetics | [ |
| Textile inks | [ | |
| Detergents | [ | |
| Adhesives | [ | |
| Welding | [ | |
| Building insulation | [ | |
| Biodegradable packaging | [ | |
| Food and drinks | Ice cream production | [ |
| Binder and thickener | [ | |
| Beer foam stabilizer | [ | |
| Confectionery and gastronomy in general | [ | |
| Aquaculture | Binder for food | [ |
| Paper industry | Thickener | [ |
| Arts and crafts | Taxidermy molds | [ |
| Leisure industry | Protective masks | [ |
Figure 1Chemical structure of alginate and alginate gelling: (a) β-(1→4)-D-mannuronic acid (M) and α-(1→4)-L-guluronic acid (G) blocks; (b) egg-box model; (c) calcium coordination described by the pair of guluronate chains in calcium alginate junction zones. Dark circles represent the oxygen atoms involved in the coordination of the calcium ion. Adapted with permission from reference [93]. Copyright 2007 American Chemical Society.
Figure 2Worldwide geographical areas where some types of algae are used for alginate production. Created with BioRender.
The main alginate types from brown algae depend on the source, M/G ratio, molecular weight, and viscosity. Nd: not determined.
| Source | M (%) | G (%) | Molecular Weight (kDa) | Viscosity (dL/g) | References |
|---|---|---|---|---|---|
|
| 25–35 | 75–65 | 91.902 | 6.4 | [ |
|
| 53–60 | 40–47 | 114–132 | 2.4 | [ |
|
| 61 | 39 | 146–264 | 12.1 | [ |
|
| 53.4–59 | 41–46.6 | 125–154.9 | 2.5 | [ |
|
| 54.2 | 45.8 | 300 | 6.3 | [ |
|
| 44–56 | 44–56 | 110–194 | 5.26–9.10 | [ |
|
| 65–72 | 28–35 | 770 | 15.4 | [ |
|
| 46 | 54 | 177.3 | 2.8 | [ |
|
| 41 | 59 | 106.6 | Nd | [ |
|
| 68–71 | 29–32 | Nd | 7.82 | [ |
Genes involved in the production of alginate by bacteria and their gene products.
| Gene | Product | Reference |
|---|---|---|
| algA | Phosphomannose isomerase/GDP-mannose pyrophosphorylase | [ |
| algB | ntrC | [ |
| algC | Phosphomannomutase | [ |
| algD | GDP-mannose dehydrogenase | [ |
| algF | O-Acetylation | [ |
| algG | Mannuronan C-5 epimerase | [ |
| algI | O-Acetylation | [ |
| algL | Alginate lyase | [ |
| algR1 | Regulatory molecules | [ |
| algS | Anti σ factor | [ |
Main alginate types produced from different bacterial cultures, M/G ratios, and characteristics of bacteria.
| Source | M (%) | G (%) | Features | References |
|---|---|---|---|---|
|
| 70 | 30 | Mucoid biofilms | [ |
| 60–73 | 27–40 | 1.4–1.8 of polydispersity index | [ | |
|
| 6–75 | 25–94 | Encystment process or biofilm | [ |
|
| 78–63 | 22–37 | 1.5–1.8 of polydispersity index | [ |
|
| 74 | 26 | Mucoid biofilms | [ |
Figure 3Film composite structures formed by calcium alginate and graphene oxide (GO). Increasing concentrations of GO in the range of 0–1% w/w. The opacity is presented as mean ± standard deviation in the base part of the samples. Reprinted with permission from Elsevier [71].
Figure 4Transmission electron microscopy (TEM) captures of carbon nanofibers (CNFs) (a) and ultrathin sections of calcium-cross-linked alginate with CNFs at 1% w/w ratio (b); cryo-scanning electron microscopy (cryoSEM) of calcium-crosslinked alginate films, neat (c,e) and with CNFs (d,f), hydrated at 26 ± 0.5 °C and 37 ± 0.5 °C for 1 day, respectively. Reprinted with permission from Elsevier [68].
Figure 5Sequential oxidation of alginate to yield alginate oxidized by sodium periodate [307].
Figure 6Poly(aldehyde guluronate) gels covalently cross-linked with adipic acid dihydrazide. Reprinted with permission from [308]. Copyright 2013 American Chemical Society.
Figure 7Results of the antibacterial test of CNFs in alginate films. Control alginate films without CNFs (a) and alginate films with a low amount (0.1% w/w) of CNFs (b) against the methicillin-resistant Staphylococcus epidermidis (MRSE) bacteria by the agar disk diffusion method at 37 °C after 24 h of incubation. The bacterial inhibitory halo produced by the antibacterial material film of calcium alginate/CNFs can be clearly observed (red arrow) [133].
Figure 8Summary illustration of extraction, crosslinking, central alginate manipulation, encapsulation, and scaffold formation techniques, such as electrospinning, 3D printing, freeze-drying, gas foaming, microfluidic gas foaming, and the porogen leaching technique. Created with BioRender.com.
Alginate-based scaffolds: fabrication method, materials combined with alginate, pore size/shape, porosity, regenerative field, year, and reference.
| Scaffold Fabrication Method | Materials Combined with Alginate | Pore Size/Shape | Porosity | Regenerative Field | Year | Ref. |
|---|---|---|---|---|---|---|
| Freeze-drying method | None | 200–300 µm | 90% | Tissue regeneration | 2002 | [ |
| Hydroxyapatite | 150 µm | >82% | Bone | 2004 | [ | |
| Chitosan | 200 µm | 84–88% | Cartilage | 2008 | [ | |
| Sulfate | 120 ± 30 µm | >90% | Vascularization | 2009 | [ | |
| Poly (lactic-co-glycolic acid)/calcium phosphate | 100–200 µm | 89.24% | Bone | 2009 | [ | |
| RGD | 88 µm | >90% | Cartilage | 2010 | [ | |
| RGD | 50–100 µm | >90% | Cardiac tissue engineering | 2011 | [ | |
| Curcumin, chitosan and collagen | 50–250 µm | - | Diabetic wound healing | 2016 | [ | |
| Collagen | 200–700 µm | 65–90% | Stem cell culture | 2018 | [ | |
| PCL:gelatin electrospun mat, and kartogenin-PLGA nanoparticles | 78.6 µm | 92.4% | Tissue engineering | 2021 | [ | |
| 3D printing/Bioprinting | MBG | 300–420 µm | 49–70% | Bone | 2012 | [ |
| PCL | 388–499 µm | - | Bone | 2012 | [ | |
| Calcium phosphate | 200–900 µm | 48–75% | Osteochondral regeneration | 2013 | [ | |
| β-TCP | 551–875 µm | 23–52% | Bone tissue engineering | 2014 | [ | |
| Tricalcium phosphate (TCP) | - | >80% | Bone | 2016 | [ | |
| Gelatin | - | 40–75% | Tissue regeneration | 2016 | [ | |
| BFP1 | - | - | Bone regeneration | 2017 | [ | |
| Graphene oxide | - | - | Chondroinductive | 2020 | [ | |
| Gelatin | <500 µm | 60–70% | Bone regeneration | 2021 | [ | |
| Polyethylene glycol | 291.4 μm | - | Delivery of insulin | 2022 | [ | |
| Electrospinning | PEO | - | - | Tissue regeneration | 2010 | [ |
| Chitosan and PEO | - | - | Tissue regeneration | 2011 | [ | |
| Gelatin | - | - | Corneal tissue engineering | 2013 | [ | |
| PCL and ethanol treatment | - | - | Tissue regeneration | 2013 | [ | |
| PCL | 821 ± 55 µm | 92% | Bone | 2014 | [ | |
| Magnesium oxide | 2–50 µm | Low | Tissue regeneration | 2017 | [ | |
| Porogen leaching | Poly(D, L-lactic acid) | 450–900 µm | 84.24–90.75% | Bone | 2008 | [ |
| Gelatin | 204 ± 58 µm | 97.26 ± 0.18% | Cell culture for regeneration | 2015 | [ | |
| Collagen | 700 µm | - | Cell cultures | 2018 | [ | |
| Gelatin/PVA | 104.5 ± 15.9 µm | 74.5 ± 15.9% | Meniscus fibrocartilage | 2018 | [ | |
| Vaterite/Crystals | 10–500 µm | - | Tissue regeneration | 2019 | [ | |
| Four-step process: preparation, cross-linking, freezing and lyophilization | - | 50–200 µm | >90% | Vascularization and generation of embryos | 2004 | [ |
| Chitosan | 100–300 µm | - | Cartilage | 2005 | [ | |
| Solution and crosslinking | Fibroblast growth factor | 100–500 µm | >90% | Vascularization | 2003 | [ |
| Thermally induced phase separation and subsequent sublimation of the solvent | Chitosan | 100–300 µm | 91.94 ± 0.9% | Bone | 2005 | [ |
| Co-precipitation | HAp/chitosan | 50–100 µm | 79–85% | Bone and other tissues | 2008 | [ |
| Sol–gel synthesis | Bioactive glass/polyvinyl alcohol | 200–500 µm | - | Trabecular bone | 2009 | [ |
| Homogenizing | Chitosan on PEC gel | 100 µm | - | Release of growth factor for tissue regeneration | 2009 | [ |
| Lyophilization | Chitosan/Hydroxyapatite | 80–200 µm | >70% | Tissue regeneration | 2010 | [ |
| Core/shell nozzle of a cryogenic | Collagen | 100–200 µm | >90% | Skin tissue regeneration | 2011 | [ |
| Modified Solid-Freeform | Cells (MC3T3-E1) | 300 µm | - | Tissue regeneration in general | 2012 | [ |
| Three monitorized precision linear stages | Chitosan | - | 66% | - | 2014 | [ |
| Binary polymer system | Felodipine Fibroin | - | 49–62% | Silk fibroin | 2020 | [ |
| Solvent casting technique | TiO2/Chitosan | None | - | Bone regeneration | 2020 | [ |
| 3D Printing (FDM)/freeze-drying/coating | PLA and hydroxyapatite | Circle | 44–36% | Bone regeneration | 2021 | [ |
| 3D printing and impregnating techniques | Chitosan/alginate/hydroxyapatite | 2–3 mm | - | Cartilage regeneration | 2022 | [ |